DocWire News Editors

DocwireNews

Treatment with umbralisib plus ublituximab was associated with significant improvements in progression-free survival (PFS) compared with standard-of-care chemoimmunotherapy in patients with treatment-na&iuml;ve and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), according to results from the phase III UNITY-CLL trial presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition.John Gribben, MD, of the Queen Mary University of London, and researchers, explained that umbralisib plus ublituximab has previously demonstrated promising activity and good tolerability in heavily pre-treated patients with CLL.In the UNITY-CLL trial, a total of 421 treatment-na&iuml;ve and R/R patients with CLL were randomly assigned to either oral umbralisib 800 mg once daily plus intravenous (IV) ublituximab 900 mg (n=210) or IV obinutuzumab 1,000 mg plus oral chlorambucil 0.5 mg/kg (n=211). The primary endpoint was PFS, and key secondary endpoints included overall response rate (ORR) and safety.Overall, the median age of the study population was 67 years (range, 36-91 years). Approximately 57% of patients (n=240) were treatment-na&iuml;ve, and 43% (n=181) presented to the study with R/R CLL.After a median follow-up of 36.2 months, treatment with the umbralisib/ublituximab combination regimen was associated with significantly prolonged PFS compared with obinutuzumab and chlorambucil (median, 31.9 vs. 17.9 months, respectively; P&lt;0.0001). The ORR, assessed by an independent review committee, was also higher with umbralisib plus ublituximab (83.3% vs. 68.7%; P&lt;0.001).Treatment discontinuation due to adverse events (AEs) was reported in 16.5% of patients on umbralisib plus ublituximab and 7.6% of patients on obinutuzumab and chlorambucil. Select grade 3/4 AEs of interest in both groups included neutropenia, thrombocytopenia, diarrhea, infusion related reaction, colitis, and pneumonitis (2.9% vs. 0%).

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

Umbralisib Plus Ublituximab Prolongs PFS in Treatment-Naïve, Relapsed/Refractory CLL

ASH Annual Meeting 2020

Treatment with umbralisib plus ublituximab was associated with significant improvements in progression-free survival (PFS) compared with standard-of-care chemoimmunotherapy in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe